FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in average-risk adults 45 and older after the PREEMPT CRC study in more than 48,000 asymptomatic adults showed 81.1% sensitivity for colorectal cancer, 13.7% sensitivity for advanced precancerous lesions, and 90.4% specificity for advanced colorectal neoplasia. Abbott plans a U.S. launch this fall, adding a blood-draw option aimed at some of the roughly 60 million Americans overdue for recommended screening.

Why It Matters To Oncology

• Colorectal cancer is the second-leading cause of cancer-related death in the U.S., and broader screening uptake could shift diagnosis earlier.

• SimpleScreen analyzes cell-free DNA from blood, expanding the liquid biopsy toolkit in oncology from treatment selection toward population screening.

• Limits remain clinically important: guidelines still favor colonoscopy and stool-based tests, and any positive blood test still requires follow-up colonoscopy.

• The low 13.7% sensitivity for advanced precancerous lesions may temper enthusiasm among clinicians focused on interception and prevention.

The Financials

• Abbott will exclusively commercialize SimpleScreen in the U.S. and will pay Freenome a $100 million milestone tied to the FDA approval.

• Freenome said the test meets Medicare coverage criteria, a key step for adoption if reimbursement is secured.

• The approval positions SimpleScreen against Guardant Health’s Shield, another FDA-approved blood test in primary CRC screening.

What They're Saying

• “The most effective screening test is the one a person will actually complete,” said Aasma Shaukat, co-lead investigator of PREEMPT CRC.

• Shaukat added that a blood-based test offers “another way to reach unscreened patients.”

• In a recent FirstWord poll, about half of physicians said they would reserve blood tests for patients who refused colonoscopy or stool testing.

• Among primary care doctors, 44% said stronger evidence for advanced precancerous lesion detection would make them more willing to use blood tests more broadly.

What's Next

• Abbott plans to launch the test in the U.S. this fall.

• Freenome recently reported stronger performance from an updated next-generation version and plans to seek supplemental FDA approval.

• The company expects the American Cancer Society to add SimpleScreen to its guidelines by name, which could accelerate uptake.

• Key watchpoints for clinicians and developers: real-world adherence gains, payer coverage, and whether next-generation performance improves detection of advanced precancerous lesions.